+86-025-52300628
- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
English
Views: 0 Author: Site Editor Publish Time: 2025-02-26 Origin: Site
Cancer remains one of the leading causes of death globally, but advancements in anti-cancer drug development have significantly improved survival rates. This article explores the most common cancer drugs, their classifications, pricing trends, and innovations, while answering key questions about modern oncology treatments.
Chemotherapy drugs form the backbone of conventional cancer treatment. These anti-cancer drugs work by targeting rapidly dividing cells, though they lack specificity and often affect healthy tissues. Key examples include:
Paclitaxel: Derived from yew trees, it disrupts microtubule function to halt cell division.
Cisplatin: A platinum-based compound that cross-links DNA, preventing replication.
According to the World Health Organization (WHO), platinum-based drugs like cisplatin are used in 60% of solid tumor treatments, including lung and ovarian cancers.
Targeted therapies revolutionized oncology by focusing on molecular abnormalities in cancer cells. Common anti-cancer drugs in this category include:
| Drug Name | Target Protein | Cancer Type |
|---|---|---|
| Trastuzumab | HER2 | Breast Cancer |
| Imatinib | BCR-ABL | Chronic Myeloid Leukemia |
Sino Biopharmatech’s LYO-1000 freeze-drying technology ensures the stability of monoclonal antibodies like trastuzumab, critical for maintaining efficacy during storage.
Pembrolizumab (Keytruda®), a new cancer drug, blocks the PD-1 protein, enabling the immune system to attack tumors. By 2023, it had become the world’s top-selling oncology drug, with annual revenues exceeding $25 billion. Key applications include:
Non-small cell lung cancer (NSCLC)
Melanoma
This anti-cancer drug requires precise bioreactor conditions, such as those provided by Sino Biopharmatech’s BioReactor-5000, which maintains pH and temperature within ±0.1% accuracy.
CAR-T therapies like Tisagenlecleucel (Kymriah®) genetically modify a patient’s T-cells to target cancer. While effective, costs exceed $500,000 per dose, highlighting disparities in cancer medicine price lists.
Lyophilization (freeze-drying) is critical for stabilizing biologics. For example, bevacizumab (Avastin®) relies on Sino Biopharmatech’s LYO-2000 system to reduce protein denaturation risks, extending shelf life by 18 months.
Traditional batch processing for anti-cancer drugs takes 14 days, but continuous systems like SinoBio-StreamLine cut this to 7 days. Benefits include:
| Parameter | Batch Process | Continuous Process |
|---|---|---|
| Production Time | 14 days | 7 days |
| Cost per Dose | $ 1,200 | $ 800 |
| API Waste | 15% | 5% |
This advancement helps lower cancer medicine prices, making treatments like pembrolizumab more accessible.
The top 5 anti-cancer drugs by usage are:
Paclitaxel (chemotherapy)
Cisplatin (chemotherapy)
Trastuzumab (targeted therapy)
Pembrolizumab (immunotherapy)
Imatinib (targeted therapy)
Yes. New cancer drug names like Enhertu® (2022 FDA-approved) show 50% higher response rates in HER2-low breast cancer compared to older therapies.
Chemotherapy: Cytotoxic agents (e.g., cisplatin).
Targeted Therapies: Monoclonal antibodies (e.g., trastuzumab).
Immunotherapy: Checkpoint inhibitors (e.g., pembrolizumab).
R&D costs average $2.6 billion per drug, and biologics require expensive production tech like bioreactors.
AI-driven drug discovery and CRISPR-based therapies aim to reduce development timelines from 10 years to 3 years.
From traditional chemotherapy to cutting-edge CAR-T therapies, anti-cancer drugs continue to evolve. Innovations in manufacturing, such as continuous processing and lyophilization, are critical for improving accessibility and affordability. As China emerges as a leader in generic and biologic production, global cancer medicine price lists will likely become more patient-friendly, offering hope to millions worldwide.